Ami Lifesciences

What Ami Lifesciences does

Ami Lifesciences Pvt. Ltd. is a pure-play Active Pharmaceutical Ingredient (API) manufacturer headquartered in Vadodara, Gujarat, India. Established in 1997 and operating under its current name since 2006, the company runs three cGMP-certified manufacturing facilities in Gujarat — Karakhadi (750 KL), Bavla (315 KL), and Ankleshwar (255 KL) — totaling approximately 1,320 KL of reactor volume across 136 reactors ranging from 100L to 16MT, with 1,500 metric tons of annual production capacity spread over 150+ acres. Its commercial portfolio includes 88+ APIs across Cardiovascular, Anti-Diabetics, CNS, and Respiratory therapeutic areas, serving 300+ global clients across 60+ countries.

The company's core technology is built around complex chemistry capabilities, including cryogenic reactions to -80°C, high-pressure hydrogenation (30 kg/cm², 180°C), pyrophoric reaction handling, and a 40+ reaction-type library, supported by advanced analytical infrastructure (HPLC, UPLC, GC-MS, LC-MS, ICP-MS, XRD, FT-IR, UV-Vis). Backward integration on all key molecules anchors cost leadership and supply-chain assurance. The product offering comprises API manufacturing as the primary revenue stream and CMO/CDMO exclusive synthesis services as a complementary line targeting innovator pharmaceutical companies. Pricing is quote-based and not publicly disclosed.

The business operates a direct B2B enterprise sales model, leveraging global pharmaceutical trade exhibitions (CPI Worldwide events in Japan, Korea, China, Milan, Barcelona, India; DCAT Week; ChemOutsourcing; PharmaConex) as primary demand-generation channels, supported by dedicated sales teams in Vadodara and Mumbai. Regulatory positioning is a core moat: 69 DMFs, 36 USDMFs, 20 CEPs, 39 KDMFs, 12 CADIFA, and 3 PMDA filings cover US, EU, Japan, Korea, Brazil, Mexico, and China markets, with site approvals from USFDA (EIR for Karakhadi in December 2024), EDQM, ANVISA, MFDS, COFEPRIS, WHO GMP, and EU-GMP. The company employs 1,001-5,000 people, received a $40M growth investment from Kedaara Capital in February 2020, and is led by founder-Chairman Girish Chovatia, supported by CEO Amit Kaptain and a senior team drawn from Dr. Reddy's, Glenmark, Wockhardt, Ipca, Cadila, and Alembic.

Name

Ami Lifesciences

Legal name

Ami Lifesciences Pvt. Ltd.

Website

https://amilifesciences.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ami Lifesciences is a pure-play Active Pharmaceutical Ingredient manufacturer headquartered in Vadodara, India, operating three cGMP-certified facilities producing 88+ commercial APIs for generic drug makers, innovator pharmaceutical companies, and formulators across 60+ countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Active pharmaceutical ingredients
• API contract manufacturing
• Generic drug manufacturing
• CDMO pharmaceutical services
• Complex API chemistry

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Manufacturing and commercial sale of Active Pharmaceutical Ingredients (APIs) to generic pharmaceutical companies, innovator companies, and formulators worldwide. The company offers 88+ commercial APIs across therapeutic areas including Cardiovascular, Anti-Diabetics, CNS, and Respiratory, with regulatory filings including DMFs, USDMFs, CEPs, and registrations in major markets (USFDA, EDQM, ANVISA, MFDS, COFEPRIS, NMPA).
2. CMO/CDMO Services: Contract Development and Manufacturing Organization (CDMO) services providing exclusive synthesis of APIs for innovators and formulators. Services include R&D for API development and validation, scale-up from grams to tons, analytical method development, and commercial manufacturing. Revenue generated through project-based contracts with pharmaceutical innovators requiring custom API synthesis.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels4 records

Core offering

Ami Lifesciences is a pure-play manufacturer and global supplier of Active Pharmaceutical Ingredients (APIs), offering 88+ commercial APIs across therapeutic areas including Cardiovascular, Anti-Diabetics, CNS, and Respiratory, with 60+ APIs in the development pipeline. The company also provides CMO/CDMO (Contract Development and Manufacturing Organization) services for exclusive custom synthesis, supporting innovator pharmaceutical companies from early-stage API development through commercial-scale cGMP manufacturing. Vertically integrated production runs from non-GMP intermediates to GMP APIs, supported by comprehensive regulatory filings (USDMFs, CEPs, KDMFs, CADIFA, PMDA) in the US, EU, Japan, Korea, Brazil, Mexico, and China.

Product overview

Ami Lifesciences is a pure-play API (Active Pharmaceutical Ingredient) manufacturing company offering vertically integrated production from non-GMP intermediates to GMP APIs. The company operates three manufacturing sites (Karakhadi-Vadodara, Bavla-Ahmedabad, and Ankleshwar-Bharuch) with combined capacity of 1320 KL reactor volume. Their product portfolio includes 73+ commercial APIs across therapeutic areas (Cardiovascular, Anti-Diabetics, CNS, Respiratory) and 60+ APIs under development. Core offerings encompass API Manufacturing, CMO/CDMO Services for exclusive synthesis, Complex Chemistry Capabilities (cryogenic reactions, hydrogenation, pyrophoric handling), Analytical Development Lab Services, Particle Size Distribution Services, and Stability Studies. The company provides regulatory support with filings across USFDA, EDQM (CEP), ANVISA, PMDA, COFEPRIS, MFDS, and NMPA.

Differentiator

Problem solved

Functional benefit

Products and services

• Commercial API Manufacturing Vertically integrated manufacturing and commercial sale of 88+ Active Pharmaceutical Ingredients (APIs) from non-GMP intermediates to GMP APIs, covering Cardiovascular, Anti-Diabetics, CNS, and Respiratory therapeutic areas for generic and innovator pharmaceutical companies worldwide. Supported by 69 DMFs, 36 USDMFs, 20 CEPs, 39 KDMFs, 12 CADIFA, and 3 PMDA filings.
• CMO/CDMO Services Contract Development and Manufacturing Organization (CDMO/CMO) services providing exclusive synthesis of APIs for innovator pharmaceutical companies and formulators, covering R&D, API development and validation, analytical method development, scale-up from grams to tons, and commercial cGMP manufacturing across every stage of drug development.
• APIs Under Development Pipeline of 60+ Active Pharmaceutical Ingredients currently in development, available for inquiry and partnership through the company's sales contacts. Represents upcoming additions to the commercial API portfolio across therapeutic categories.

Quantifiable outcome

• Highest USDMF filings (#14 globally) in H1 2023 timeframe
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• United Way of BarodacoreOthers · 1 April 2022CSR collaboration partnership for rural community development. Jointly launched the Rural Rising Project in April 2022 at Karakhadi, Vadodara, focusing on integrated rural development including quality education, healthcare access, STEM enhancement, infrastructure provision, and community development. Project aims to enhance rural communities in Padra Block, Vadodara.

Scale indicators12 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Piramal Pharma Solutions: Indian CDMO providing complex API development and manufacturing services to innovator pharma globally. Comparable in exclusive synthesis, complex chemistry, and technology transfer capabilities targeting innovator customers.
• Laurus Labs: Indian API manufacturer and CDMO with similar business model spanning commercial API production and contract development services. Closest direct comparable in scale and strategic positioning, including specialty API focus and global regulatory footprint.
• Divi's Laboratories: Larger Indian API manufacturer focused on generics and custom synthesis with deep regulatory portfolio across US, EU, and Japan. Comparable in vertical integration, complex chemistry capabilities, and global customer base among innovator and generic pharma.
• SMS Pharmaceuticals: Indian API manufacturer with similar Hyderabad-based manufacturing footprint (analogous to Gujarat cluster), comparable DMF strategy, and overlap in cardiovascular and CNS therapeutic areas.
• Jubilant Pharmova: Indian CDMO and API manufacturer serving both generic and innovator pharma with regulatory filings across major markets. Directly comparable business model combining contract manufacturing with proprietary API portfolio.
• Neuland Laboratories: Indian pure-play API manufacturer with parallel CDMO offerings, similar therapeutic area breadth, USDMF-driven strategy, and comparable scale (1,000+ employees, multi-site Indian manufacturing, USFDA/EDQM approvals).
• Granules India: Indian API + finished formulations manufacturer with global regulatory filings and CDMO services. Comparable regulatory strategy across USFDA/EDQM and overlap in cardiovascular/diabetic therapeutic areas.
• Suven Pharmaceuticals: Indian API + CDMO company focused on specialty molecules for innovator and generic customers. Comparable scale, business model, and CRAMS positioning targeting global pharma customers.

Broad incumbents

• Aurobindo Pharma: Larger Indian pharmaceutical company with a substantial API manufacturing division alongside finished dosage generics. Broader incumbent with overlapping API capabilities and shared customer base among global generic and innovator pharma.
• Dr. Reddy's Laboratories: Large Indian pharma with active pharmaceutical ingredient manufacturing and global regulatory footprint. Broad incumbent that overlaps with Ami on API supply and custom manufacturing services to global customers; several Ami leadership alumni previously worked at Dr. Reddy's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amilifesciences
• Xx.com/AmiLifesciences

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ami Lifesciences